Cite
A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors.
MLA
Stein, Mark N., et al. “A Phase I Study of AT-101, a BH3 Mimetic, in Combination with Paclitaxel and Carboplatin in Solid Tumors.” Investigational New Drugs, vol. 38, no. 3, June 2020, pp. 855–65. EBSCOhost, https://doi.org/10.1007/s10637-019-00807-2.
APA
Stein, M. N., Goodin, S., Gounder, M., Gibbon, D., Moss, R., Portal, D., Lindquist, D., Zhao, Y., Takebe, N., Tan, A., Aisner, J., Lin, H., Ready, N., & Mehnert, J. M. (2020). A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors. Investigational New Drugs, 38(3), 855–865. https://doi.org/10.1007/s10637-019-00807-2
Chicago
Stein, Mark N., Susan Goodin, Murugeson Gounder, Darlene Gibbon, Rebecca Moss, Daniella Portal, Diana Lindquist, et al. 2020. “A Phase I Study of AT-101, a BH3 Mimetic, in Combination with Paclitaxel and Carboplatin in Solid Tumors.” Investigational New Drugs 38 (3): 855–65. doi:10.1007/s10637-019-00807-2.